Che-Yi Chou1,2,3,4, Chin-Chung Tseng5, Jin-Bor Chen6, Chin-Chuan Hung7, Chiu-Ching Huang1,3. 1. College of Medicine, China Medical University, Taichung, Taiwan. 2. Division of Nephrology, Asia University Hospital, Taichung, Taiwan. 3. Division of Nephrology and Kidney Institute, China Medical University Hospital, Taichung, Taiwan. 4. Department of Post-Baccalaureate Veterinary Medicine, Asia University, Taichung, Taiwan. 5. Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 6. Division of Nephrology, Kaohsiung Chang Gung Memorial Hospital of The C.G.M.F, Kaohsiung, Taiwan. 7. School of Pharmacy, China Medical University, Taichung, Taiwan.
Abstract
BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis (PD). So far, there is no biomarker-based prediction tool available for EPS. Matrix metalloproteinase-2 (MMP-2) is a protein involved in the breakdown of the extracellular matrix, and the effluent MMP-2 can be a potential biomarker of EPS. This study is aimed at developing a nomogram for EPS based on effluent MMP-2 levels. Patients and Methods. We enrolled 18 EPS patients and 90 gender-matched PD patients without EPS in this cross-sectional case-controlled study. The effluent MMP-2 levels and possible risk factors for EPS were analyzed using multivariable logistic regression, and a nomogram was developed. The nomogram was validated using 200 bootstrap resamples to reduce overfit bias. RESULTS: The effluent MMP-2 levels in EPS patients were significantly higher than those in normal PD patients (p < 0.001, Manny-Whitney U test). Effluent MMP-2 levels and PD duration were independently associated with EPS risks (p < 0.001 and p = 0.001) in multivariate logistic regression. A nomogram based on MMP-2 levels and PD duration was proposed. The AUC of MMP-2 was 0.824, and the AUC of the nomogram was 0.907 (p = 0.05). CONCLUSION: A nomogram based on effluent MMP-2 levels and PD duration may predict EPS with high accuracy.
BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of peritoneal dialysis (PD). So far, there is no biomarker-based prediction tool available for EPS. Matrix metalloproteinase-2 (MMP-2) is a protein involved in the breakdown of the extracellular matrix, and the effluent MMP-2 can be a potential biomarker of EPS. This study is aimed at developing a nomogram for EPS based on effluent MMP-2 levels. Patients and Methods. We enrolled 18 EPS patients and 90 gender-matched PD patients without EPS in this cross-sectional case-controlled study. The effluent MMP-2 levels and possible risk factors for EPS were analyzed using multivariable logistic regression, and a nomogram was developed. The nomogram was validated using 200 bootstrap resamples to reduce overfit bias. RESULTS: The effluent MMP-2 levels in EPS patients were significantly higher than those in normal PD patients (p < 0.001, Manny-Whitney U test). Effluent MMP-2 levels and PD duration were independently associated with EPS risks (p < 0.001 and p = 0.001) in multivariate logistic regression. A nomogram based on MMP-2 levels and PD duration was proposed. The AUC of MMP-2 was 0.824, and the AUC of the nomogram was 0.907 (p = 0.05). CONCLUSION: A nomogram based on effluent MMP-2 levels and PD duration may predict EPS with high accuracy.
Authors: Gowrie Balasubramaniam; Edwina A Brown; Andrew Davenport; Hugh Cairns; Barbara Cooper; Stanley L S Fan; Ken Farrington; Hugh Gallagher; Patrick Harnett; Sally Krausze; Simon Steddon Journal: Nephrol Dial Transplant Date: 2009-02-11 Impact factor: 5.992
Authors: M A Mateijsen; A C van der Wal; P M Hendriks; M M Zweers; J Mulder; D G Struijk; R T Krediet Journal: Perit Dial Int Date: 1999 Nov-Dec Impact factor: 1.756
Authors: Vasileios Zavvos; Anthony T Buxton; Caroline Evans; Mark Lambie; Simon J Davies; Nicholas Topley; Martin Wilkie; Angela Summers; Paul Brenchley; Dimitrios S Goumenos; Timothy S Johnson Journal: Kidney Int Date: 2017-07-01 Impact factor: 10.612
Authors: G Del Peso; J A Jiménez-Heffernan; M A Bajo; L S Aroeira; A Aguilera; A Fernández-Perpén; A Cirugeda; M J Castro; R de Gracia; R Sánchez-Villanueva; J A Sánchez-Tomero; M López-Cabrera; R Selgas Journal: Kidney Int Suppl Date: 2008-04 Impact factor: 10.545
Authors: Ceri A Fielding; Gareth W Jones; Rachel M McLoughlin; Louise McLeod; Victoria J Hammond; Javier Uceda; Anwen S Williams; Mark Lambie; Thomas L Foster; Chia-Te Liao; Christopher M Rice; Claire J Greenhill; Chantal S Colmont; Emily Hams; Barbara Coles; Ann Kift-Morgan; Zarabeth Newton; Katherine J Craig; John D Williams; Geraint T Williams; Simon J Davies; Ian R Humphreys; Valerie B O'Donnell; Philip R Taylor; Brendan J Jenkins; Nicholas Topley; Simon A Jones Journal: Immunity Date: 2014-01-09 Impact factor: 31.745